Evidence map›Paper›PMID 33072616›Full record

ReviewFrontiers in cellular and infection microbiology2020

Control of Immediate Early Gene Expression for Human Cytomegalovirus Reactivation.

Donna Collins-McMillen, Jeremy Kamil, Nathaniel Moorman, Felicia Goodrum

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Host-encoded CTCF regulates human cytomegalovirus latency via chromatin looping.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Donna Collins-McMillenDepartment of Immunobiology and BIO5 Institute, University of Arizona, Tucson, AZ, United States.
Jeremy KamilDepartment of Microbiology and Immunology, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, United States.
Nathaniel MoormanDepartment of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Felicia GoodrumDepartment of Immunobiology and BIO5 Institute, University of Arizona, Tucson, AZ, United States.
University of Arizona · USLouisiana State University Health Sciences Center Shreveport · USUniversity of North Carolina at Chapel Hill · US

Funding

The Administrative CoreP01AI127335 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Patrizia Caposio · 2017 to 2026
$24.6M
COBRE Center for Molecular and Tumor VirologyP30GM110703 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI SAPP, MARTIN · 2014 to 2018
$4.8M
The role of host and viral translation factors during HCMV infectionR01AI103311 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MOORMAN, NATHANIEL J · 2013 to 2022
$3.9M
Molecular Switch Regulating Human Cytomegalovirus Replicative and Latent StatesR01AI143191 · NIAID · UNIVERSITY OF ARIZONA · PI GOODRUM, FELICIA D, KAMIL, JEREMY PHILLIP · 2018 to 2022
$2.7M
Hybrid Sequencing to Define the Full-Length Transcriptome of Double Stranded DNA VirusesR21AI123811 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MOORMAN, NATHANIEL J, PRINS, JAN F · 2016 to 2017
$413k
The role of host and viral translation factors during HCMV infectionR56AI103311 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MOORMAN, NATHANIEL J · 2018 to 2018
$74k
NIAID NIH HHS P01 AI127335NIAID NIH HHS R01 AI103311NIAID NIH HHS R01 AI143191NIAID NIH HHS R21 AI123811NIAID NIH HHS R56 AI103311NIGMS NIH HHS P30 GM110703
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is a beta herpesvirus that persists for life in the majority of the world's population. The persistence of HCMV in the human population is due to the exquisite ability of herpesviruses to establish a latent infection that evades elimination by the host immune response. How the virus moves into and out of the latent state has been an intense area of research focus and debate. The prevailing paradigm is that the major immediate early promoter (MIEP), which drives robust expression of the major immediate early (MIE) transactivators, is epigenetically silenced during the establishment of latency, and must be reactivated for the virus to exit latency and re-enter productive replication. While it is clear that the MIEP is silenced by the association of repressive chromatin remodeling factors and histone marks, the mechanisms by which HCMV de-represses MIE gene expression for reactivation are less well understood. We have identified alternative promoter elements within the MIE locus that drive a second or delayed phase of MIE gene expression during productive infection. In the context of reactivation in THP-1 macrophages and primary CD34+ human progenitor cells, MIE transcripts are predominantly derived from initiation at these alternative promoters. Here we review the mechanisms by which alternative viral promoters might tailor the control of viral gene expression and the corresponding pattern of infection to specific cell types. Alternative promoter control of the HCMV MIE locus increases versatility in the system and allows the virus to tightly repress viral gene expression for latency but retain the ability to sense and respond to cell type-specific host cues for reactivation of replication.

Indexed as

CytomegalovirusCytomegalovirus InfectionsGene Expression Regulation, ViralGenes, Immediate-EarlyHumansVirus Latencyalternative promoter usagecytomegalovirusherpesviruslatencymajor immediate early (MIE) promoterreactivation

Identifiers

PMID33072616
PMCPMC7533536
OpenAlexW3084464642

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.